Duchenne Muscular Dystrophy (DMD) influences millions globally, necessitating a robust market for effective treatments. The present DMD treatment landscape is characterized here by the focus on symptom management and supportive care. However, recent developments in gene therapy and drugs are paving the way for potential curative treatments. Clinic